Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

@inproceedings{Noguchi2013EfficacyOE,
  title={Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2},
  author={Shinzaburo Noguchi and Norikazu Masuda and Hiroji Iwata and Hirofumi Mukai and Jun Horiguchi and Puttisak Puttawibul and Vichien Srimuninnimit and Yutaka Tokuda and Katsumasa Kuroi and Hirotaka Iwase and Hideo Inaji and Shozo Ohsumi and Woo Chul Noh and Takahiro Nakayama and Shinji Ohno and Yogesh Kumar Rai and Byeong Woo Park and Ashok Panneerselvam and Mona El-Hashimy and Tetiana Taran and Tarek Sahmoud and Yoshinori Ito},
  booktitle={Breast cancer},
  year={2013}
}
BACKGROUND The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR(+)) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be influenced by ethnicity (Sekine et al. in Br J Cancer 99:1757-62, 2008). Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported. METHODS Patients were randomized… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Organization fact sheet no 297

  • WHO. World Healt
  • Feb . http://www.who.int/mediacentre/factsheets…
  • 2012

Similar Papers

Loading similar papers…